我国非国家组织药品集中采购模式比较

目的比较分析我国各省市的药品集中采购方案及相关政策,探讨各地非国家组织药品集中采购模式的特点。方法围绕采购内容、采购规则等比较分析各地的非国家组织药品集中采购模式的特点,以及采购内容、采购环境、采购规则之间的内在关系。结果我国目前的非国家组织药品集中采购模式可划分为药品集中采购组织(group purchasing organization,GPO)、非过评仿制药带量采购、专项药品带量采购、带量议价以及分类采购框架下的带量采购5种。我国非国家组织药品集中采购的特点是分品种、分批次,以政府主导为主,执行机构主要为医疗保障局。结论目前,各地的非国家组织药品集中采购仅覆盖了部分品种的药品,对非过评仿制药进行集中采购是未来的重要趋势,建立公平、科学的质量分组规则是非国家组织药品集中采购亟待解决的重要技术问题。

Policy Comparison between Shenzhen GPO and Guangdong Medicine Exchange Center

Objective To put forward some suggestions for improving the procurement policy of Shenzhen Pharmaceutical Group.Methods The literature research and comparative research were used to compare the policies between Guangdong’s centralized drug procurement and Shenzhen Pharmaceutical Group’s procurement so as to analyze their advantages and disadvantages.Results and Conclusion The purchasing model of Shenzhen group purchasing organization(GPO)can ensure the timely supply of medicines.Besides,the cross-regional alliance system helps to achieve a true price-for-quantity exchange,and a market-based price linkage mechanism can effectively reduce drug prices.However,the online drug catalogue of Shenzhen GPO cannot fully cover the actual needs of hospitals for procurement.The market-based price linkage may lead to problems of drug quality or shortage of drugs.Therefore,the number of batches of drugs should be increased online appropriately.Meanwhile,a mechanism must be established to guarantee the supply and quality of low-priced drugs.